Skip to main content
Clinical Trials/NCT04131257
NCT04131257
Unknown
Not Applicable

Nurse-led Continuum of Care for People With Diabetes and Pre-diabetes in Nepal (NUCOD): Study Protocol for a Cluster Randomized Controlled Trial

Kathmandu University School of Medical Sciences0 sites1,236 target enrollmentDecember 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Diabetes Mellitus, Type 2
Sponsor
Kathmandu University School of Medical Sciences
Enrollment
1236
Primary Endpoint
Change in Glycated Hemoglobin (HbA1c) level
Last Updated
6 years ago

Overview

Brief Summary

The study aims to improve diabetes prevention, access to care and advocacy through a novel cost-effective nurse-led continuum of care approach that incorporates diabetes prevention, awareness, screening and management for low-income settings, and furthermore utilizes the endeavor to advocate for establishing standard diabetes program in Nepal.

Detailed Description

The purpose of this study will be to improve diabetes prevention, access to care and advocacy through a novel cost-effective nurse-led continuum of care approach that incorporates diabetes prevention, awareness, screening and management for low-income settings, and furthermore utilizes the endeavor to advocate for establishing standard diabetes program in Nepal. We will conduct a two-arm, open-masked stratified cluster randomized controlled trial of a NUrse-led COntinuum of care for people with diabetes and pre-diabetes (NUCOD), with primary care centers (Outreach centers and Government health posts) as a unit of randomization. NUCOD will be delivered through the trained diabetes nurses in the community to the intervention group and the outcomes will be compared to the enhanced usual-treatment group at 6 and 12 months of the intervention. The primary outcome will be change in glycated hemoglobin (HbA1c) level among diabetes and progression to type 2 diabetes among pre-diabetes, and implementation outcomes measured using the RE-AIM (reach, effectiveness, adoption, implementation, and maintenance) framework. Outcomes will be analyzed on an intention to treat basis. The results of this trial will provide information about the effectiveness of the NUCOD program in improving clinical outcomes for diabetes and pre-diabetes individuals, and implementation outcomes for the organization.

Registry
clinicaltrials.gov
Start Date
December 2019
End Date
December 2020
Last Updated
6 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Biraj Man Karmacharya

Associate Professor

Kathmandu University School of Medical Sciences

Eligibility Criteria

Inclusion Criteria

  • with confirmed pre-existing type II diabetes and prediabetes at the time of our screening (i.e., pre-existing diabetes or prediabetes)
  • with confirmed diagnosis of type II diabetes or prediabetes after our community screening process (i.e., newly diagnosed diabetes and prediabetes)
  • is not planning to relocate outside of the current place of living in next 2 years
  • is older than 18 years of age

Exclusion Criteria

  • are not psychologically capable of communication
  • are diagnosed as type 1 diabetes

Outcomes

Primary Outcomes

Change in Glycated Hemoglobin (HbA1c) level

Time Frame: Baseline, 6 months, 12 months

The HbA1c will be measured using Boronate affinity chromatography (Axis-Shield, Norway)

Change in the incidence of diabetes among individuals with pre-diabetes

Time Frame: 6 months, 12 months

Electronic Health Record will be used to measure the incidence of diabetes

Secondary Outcomes

  • Change in the "Adoption at the patient level" measured by the Diabetes Treatment Satisfaction Questionnaire(Baseline, 6 months, 12 months)
  • Change in the "Adoption at the patient level" measured by the Summary of Diabetes Self-Care Activities Scale(Baseline, 6 months, 12 months)
  • Change in Blood Pressure(Baseline, 6 months, 12 months)
  • Change in lipid profile levels (HDL, LDL, Triglycerides, Total cholesterol)(Baseline, 6 months, 12 months)
  • Change in the "Reach" of people participating in the program(6 months, 12 months)
  • Change in the "Adoption at the clinic level"(6 months, 12 months)
  • Change in Body Mass Index(Baseline, 6 months, 12 months)

Similar Trials